Élite Selank

Description

Élite Selank is an innovative peptide supplement recently launched by MetaHuman. This advanced formulation is based on the heptapeptide derivative of the naturally occurring tetrapeptide Tuftsin, which is found in the human body and has the sequence: threoline-lysine-proline-arginine.

Le most notable biological activity of Tuftsin is its capability to activate phagocytosis of granulocytes and macrophages, therefore playing a vital role in the immune response. Elite Selank was developed with the intention of serving as a prospective treatment for anxiety et mood disorders, specifically aimed at minimizing the side effects usually associated with conventional anti-anxiety medications.

Mécanisme d'action :
Elite Selank directly interacts with the GABA (acide gamma-aminobutyrique) receptors, yet clinical studies have shown that it functions more as an allosteric effector of these receptors. This means it can modulate receptor activity without directly activating them. In addition, Elite Selank is believed to influence the metabolism of neurotransmitters such as Serotonin et Dopamine, leading to changes in gene expression that impact the neurotransmitter properties in neuronal cells.

Dosage:
To achieve the desired effects, it is recommended to take 1 capsule per day.

Contents per capsule:
– Ingrédient actif : Elite Selank Peptide
– Autres ingrédients : Gelatin (capsule), Magnesium Stearate (minimum lubricant), Rice Flour (filler)

This product is designed for adults seeking an alternative approach to managing anxiety and mood-related issues, combining cutting-edge peptide technology with the aim of promoting a better quality of life. Always consult a healthcare provider before starting any new supplement regimen.

1. Samonina, G., Kopylova, G., Zuzina, A., Trofimov, S., Medvedeva, E., & Otellin, V. (2017). The analogue of the natural peptide tuftsin, Selank, exhibits neuroprotective effects and suppresses the synthesis of lipopolysaccharides in vitro models. Bulletin of Experimental Biology and Medicine, 162(4) 519-521. Lien
2. Zozulya, A. A., Gabaeva, M. V., Sokolov, O. Y., Surkina, I. D., & Kost, N. V. (2008). Permeability of the blood–brain barrier to a new potential anti-anxiety peptide drug selank. Eksperimental’naia i Klinicheskaia Farmakologiia, 71(2), 8-12. Lien
3. Sollertinskaya, T. N., Shadrina, M. I., & Slominskii, P. A. (2007). Influence of the peptide drug selank on the expression of genes related to the metabolism of serotonin in the brain of BALB/C and C57BL/6 mice. Russian Journal of Genetics, 43(2) 181-185. Lien
4. Ershov, P. V., Melekhina, O. A., Shenkarev, Z. O., Ovchinnikova, T. V., & Ramirez, B. E. (2019). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology; 10:36. Lien
5. Medvedeva, E., Dmitrieva, V., Povarova, O., Limborska, S., Skvortsova, V., Dergunova, L., & Myasoedov, N.